Navigation Links
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release,Formulation of Bromocriptine Mesylate) Accepted for Poster,Presentation at American Diabetes Association 67th Scientific,Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, and Glycemic Control in Subjects with Type 2 Diabetes Receiving Diet, Oral Hypoglycemic, and/or Insulin Treatment Regimens," will be included in the category of Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications and displayed Saturday, Sunday and Monday, June 23-25, in the General Poster Session in the Exhibit Hall.

VeroScience is also sponsoring a corporate symposium supported by its commercialization partner for Cycloset(TM), S2 Therapeutics, Inc., that will be held in conjunction with the American Diabetes Association's 67th Scientific Sessions. The symposium, entitled "Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes," will be held on Sunday, June 24th from 5:30-7:45 AM at the Hyatt Regency Chicago, Grand F/D South. Registration and breakfast are from 5:00-5:30 AM or you can register in advance at www.veroscience.com/ada2007registration.

Cycloset(TM), an oral, quick-release formulation of bromocriptine is a centrally-acting dopamine D2 receptor agonist that is being studied as a potential therapy in the treatment of type 2 diabetes.

VeroScience is a privately held biotechnology and healthcare product development company with main offices and laboratories in Tiverton, RI. VeroScience has a large patent portfolio tha t supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology, reproduction, and oncology. VeroScience leverages its intellectual property and products in out-licensing and collaborative arrangements with appropriate industry partners.

S2 Therapeutics, a privately held specialty pharmaceutical company headquartered in Bristol, TN, is the commercialization partner for Cycloset(TM) and is the holder of an exclusive global license for the manufacture, marketing and distribution of Cycloset(TM). S2 seeks opportunities in the pharmaceutical industry through in-licensing arrangements and acquisitions of novel branded prescription pharmaceutical products.


    Contacts:

    Feinstein Kean Healthcare

    Christine Cramer, 617-761-6736

    
 
christine.cramer@fkhealth.com

CONTACT: Christine Cramer of Feinstein Kean Healthcare, +1-617-761-6736,, for VeroScience, LLC christine.cramer@fkhealth.com

Web site: http://www.veroscience.com/ada2007registration/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
2. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
5. OXiGENE Abstracts Published in ASCO Program
6. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
7. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
8. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
11. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):